Not checkedNot checked for notices yet.
Advances in pharmaceutic managements of migraine
LI Yan⁃sheng
Chinese Journal of Contemporary Neurology and Neurosurgery · 2022
doi:10.3969/j.issn.1672⁃6731.2022.02.008 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Migraine is a neurovascular disorder with great burden so that effective abortive and preventive treatment is needed. Different from the previous choice of drugs based on clinical experience, the specific treatment targeting the pathogenesis of migraine has revolutionized the management of migraine in recent years. Ditans and gepants can not only effectively relief headache and related symptoms but also be effective for those who are refractory to the abortive treatment by traditional painkillers or triptans. A variety of monoclonal antibodies against calcitonin gene⁃related peptide (CGRP) and CGRP receptor can effectively reduce headache attacks, especially when accompanied by other difficult clinical situations. This paper reviews the research progress of migraine drugs and its impact on clinical practice.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.